Network based meta-analysis prediction of microenvironmental relays involved in stemness of human embryonic stem cells

Virginie Mournetas¹,², Quentin M. Nunes²,³, Patricia A. Murray⁴, Christopher M. Sanderson¹ and David G. Fernig²

¹ Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
² Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom
³ NIHR Liverpool Pancreas Biomedical Research Unit, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom

ABSTRACT

Background. Human embryonic stem cells (hESCs) are pluripotent cells derived from the inner cell mass of in vitro fertilised blastocysts, which can either be maintained in an undifferentiated state or committed into lineages under determined culture conditions. These cells offer great potential for regenerative medicine, but at present, little is known about the mechanisms that regulate hESC stemness; in particular, the role of cell–cell and cell-extracellular matrix interactions remain relatively unexplored.

Methods and Results. In this study we have performed an in silico analysis of cell-microenvironment interactions to identify novel proteins that may be responsible for the maintenance of hESC stemness. A hESC transcriptome of 8,934 mRNAs was assembled using a meta-analysis approach combining the analysis of microarrays and the use of databases for annotation. The STRING database was utilised to construct a protein–protein interaction network focused on extracellular and transcription factor components contained within the assembled transcriptome. This interactome was structurally studied and filtered to identify a short list of 92 candidate proteins, which may regulate hESC stemness.

Conclusion. We hypothesise that this list of proteins, either connecting extracellular components with transcriptional networks, or with hub or bottleneck properties, may contain proteins likely to be involved in determining stemness.

INTRODUCTION

Human embryonic stem cells (hESCs) are pluripotent cells present in the inner cell mass of the blastocyst (Pera, Reubinoff & Trounson, 2000). They give rise in vivo to the three germ layers (ectoderm, endoderm and mesoderm) and therefore, have the ability to generate all tissues within the body. These cells can also be derived in vitro (Thomson et al., 1998), maintaining an ability to either self-renew or differentiate (Keller, 2005). Human ESCs are...
a fundamental tool for understanding human embryonic development and constituent mechanisms of differentiation (Keller, 2005). Moreover, they represent a potentially powerful tool in drug screening (Jensen, Hyllner & Bjorquist, 2009) and regenerative medicine (Aznar & Gomez, 2012; Keller, 2005; Wobus & Boheler, 2005). However, in order to mobilise the potential of hESCs, it is necessary to understand the molecular determinants of self-renewal and differentiation.

The core transcriptional network regulating pluripotency (Babaie et al., 2007; Boyer et al., 2005; Chavez et al., 2009; Marson et al., 2008; Rodda et al., 2005) is composed of three transcription factors: octamer-binding protein 4 (OCT4) (Hay et al., 2004), sex determining region Y-box 2 (SOX2) (Fong, Hohenstein & Donovan, 2008) and NANOG (Hyslop et al., 2005; Zaehres et al., 2005). Interestingly, although these transcription factors clearly drive pluripotency (Li et al., 2009; Takahashi et al., 2007), their expression is not restricted to hESCs (Atlasi et al., 2008; Leis et al., 2012; Liedtke et al., 2007; Pierantozzi et al., 2011; Zangrossi et al., 2007). Thus, stemness must in part depend on other hESC specific characteristics, such as the context of expression of these three transcription factors. Protein–protein interaction networks may provide a valuable insight into this hESC specific context (Boyer et al., 2005; Muller et al., 2008). Proteins of the cell microenvironment may also be an important part of this network (Evesenko et al., 2009; Stelling et al., 2013; Sun et al., 2012), since this is the niche where cell–cell and cell-extracellular matrix (ECM) interactions occur, allowing selective cell communication. Indeed, it was through the addition of ECM proteins and growth factors that xeno-free culture conditions for hESCs were defined (Melkoumian et al., 2010; Rodin et al., 2010). These methods have facilitated investigation of the roles that extracellular molecules, such as heparan sulfate (HS) (Stelling et al., 2013), fibroblast growth factor (FGF)-2 (Eiselleova et al., 2009; Greber et al., 2010) and activin A (Xiao, Yuan & Sharkis, 2006) play in hESC self-renewal and differentiation. However, such factors have not always been linked to specific transcriptional networks and many of the defined medium formulations do not completely sustain pluripotency (Baxter et al., 2009; Ludwig et al., 2006). Therefore, other factors involved in the maintenance of stemness must be missing. One key factor could be a wider link between ECM interactions and transcriptional networks, thereby establishing important relay mechanisms between endogenous and exogenous stemness regulators.

Data from large-scale transcriptomic and proteomic studies (Koh et al., 2012) facilitate the construction of large biological networks in which nodes and edges represent molecules and interactions respectively. Studying the topological properties of these networks may enable the elaboration of novel hypotheses. For instance, it has been shown that hubs, which are highly connected nodes within a network, are more likely to be important proteins in a protein–protein interaction network (Jeong et al., 2001), as well as bottlenecks, which are nodes with a high betweenness centrality, meaning many shortest paths within the network pass through them (Yu et al., 2007).

To gain a more global insight into the potential contribution of the cell-microenvironment to stemness, we employed an in silico systems-level approach where a meta-analysis of dozens of microarrays was performed to establish a stringent yet
more representative hESC transcriptome. Transcripts of transcriptional and extracellular proteins were used to build a putative interactome or protein–protein interaction network. The organisation of this network was then analysed to identify extracellular proteins with hub or bottleneck properties, which may be involved in determining stemness, as well as proteins connecting the extracellular factors to transcription.

MATERIALS AND METHODS

Establishing hESC and hESC-derived transcriptomes

The microarray datasets used to establish a high coverage hESC transcriptome were raw data (.CEL image files) of single channel Human Genome U133 Plus 2.0 Affymetrix microarrays downloaded from the ArrayExpress public database (Parkinson et al., 2007). Probe intensity extraction and normalisation procedures were performed with BRB-ArrayTools 4.3.0 beta 1 (Simon et al., 2007) using default median array values (selected by BRB-ArrayTools 4.3.0 beta 1) as reference. The minimum required fold change was 1.5. If less than 20% of the expression values met this value, the gene was excluded. Each individual dataset was first analysed using the three available algorithms: Robust Multi-array Analysis (RMA) (Irizarry et al., 2003), GC-RMA (Wu et al., in press) and Micro Array Suite 5.0 (MAS5.0) (Hubbell, Liu & Mei, 2002). The three lists of expressed genes were either combined to create a total list containing all expressed genes, or compared to create an intersection list containing only overlapping genes. For the hESC datasets, when the intersection list contained at least 50% of the genes of the total list, the dataset was used to perform a meta-analysis to establish the hESC transcriptome. Thus, all hESC datasets matching this criterion were grouped to be analysed together and generate the final intersection list used as the hESC transcriptome for further analysis (Fig. 1). For the hESC-derived cell datasets, if the intersection list contained at least 50% of the genes of the total list, the full transcriptome (fibroblasts and endothelial cells) was used for transcriptomic comparisons; otherwise the datasets were combined to build the final intersection list and form the hESC-derived cell transcriptome, which was used for transcriptomic comparisons (Fig. 1). The identifiers were EntrezGene IDs and Official Gene Symbol identifiers. The identifier conversion was done with the database for annotation, visualization and integrated discovery (DAVID) 6.7 (Huang, Sherman & Lempicki, 2009a; Huang, Sherman & Lempicki, 2009b).

Selection of extracellular and transcription related sub-transcriptomes

The extracellular (EC) and the transcription factor related (TF) components of the transcriptomes were extracted using the Gene Ontology (GO) database (Ashburner et al., 2000). The terms used were: GO:0005576 (extracellular region) and GO:0009986 (cell surface) for the EC component; GO:0005667 (transcription factor complex), GO:0008134 (transcription factor binding), GO:0000988 (protein binding transcription factor activity) and GO:0001071 (nucleic acid binding transcription factor activity) for the TF component. Genes involved in biological processes (e.g., cell cycle (GO:0007049), cell
Figure 1 Flow chart of the microarray dataset analysis. This flow chart describes the microarray meta-analysis process ending by the transcriptome establishment of hESC, endothelial cells, fibroblasts and mixed hESC-derived cells.
adhesion (GO:0007155), cell communication (GO:0007154), cell junction (GO:0030054) and cytoskeleton organization (GO:0007010)) were also highlighted.

By using a published list of HS binding proteins (Ori, Wilkinson & Fernig, 2008), the EC component was divided into two distinct groups: genes coding for HS binding proteins and those coding for non-HS binding proteins.

The hESC transcriptome was compared with the three different hESC-derived cell transcriptomes to establish which mRNAs were only expressed in hESC (the specific part) and which ones were expressed in all analysed transcriptomes (the common part).

**Construction and analysis of putative interactomes**

Putative interactomes were built with the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) 9.0 database (Szklarczyk et al., 2011) using interaction data from experimental/biochemical experiments and association in curated databases only, which excludes interaction predictions by neighbourhood in the genome, gene fusions, co-occurrence across genomes, co-expression and text-mining (co-mentioned in PubMed abstracts). A stringent interaction confidence of 0.7 was imposed to ensure a higher probability that the predicted links exist (Szklarczyk et al., 2011).

**Analysis of network structure**

Cytoscape 2.8.0 software (Shannon et al., 2003) and associated plug-ins were used to visualise and analyse protein–protein interaction networks. Randomised networks were created by the RandomNetworks v1.0 plug-in from the real protein–protein interaction networks. Therefore, each random network had the same number of nodes $N$ and edges $L$ as its corresponding real network. Network topological parameters, such as connected components, average degree $\langle k \rangle$, degree distribution $P(k)$, average clustering coefficient $\langle C \rangle$, clustering coefficient distribution $C(k)$ and characteristic path length $\langle l \rangle$, were computed with the NetworkAnalyster plug-in. Statistical analysis was performed using IBM SPSS Statistics 21 software.

**Enrichments analysis of interactome components**

Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa & Goto, 2000) pathway and GO Biological Processes term enrichments were processed using DAVID 6.7 (Huang, Sherman & Lempicki, 2009a; Huang, Sherman & Lempicki, 2009b) for the analysis of transcriptome subsets. Terms were recorded when the EASE score was $\leq 0.1$ and considered significantly enriched when the false discovery rate was $\leq 0.05$. Enrichment was calculated through two different ways: the ratio of the ratio of proteins belonging to the term in the analysed list and the ratio of proteins belonging to the term in Homo sapiens, or hESCs.

**Selection of candidate proteins**

Proteins with a degree $k$ in the top 20% were considered as hubs, while proteins with a betweenness in the top 20% were considered as bottlenecks (Yu et al., 2007). The EC/TF and specific/common interfaces were established from the hESC sub-interactome, constructed with STRING data (edge confidence of 0.7) and containing EC and TF components only. To be part of the EC/TF interface network, an EC node had to be connected to at least one
TF node and vice-versa. Similarly, to be part of the specific/common interface, a specific node had to be connected to a least one common node and vice-versa. In this complete (ALL_EC+TF) list of candidate proteins composed of the two interfaces, hubs and bottlenecks, only the EC nodes from the specific and common parts were kept to establish the final (C+S_EC) short list of candidate proteins (Fig. 2). The KEGG pathway and GO Biological Processes term enrichments were processed as previously. Statistical analysis was performed using IBM SPSS Statistics 21 software and presented as mean ± SEM.

RESULTS
The hESC transcriptome
To discover new regulators of hESC pluripotency, 24 hESC microarrays were analysed from four different datasets (Table 1). A total of 8,934 genes were found to be expressed, which
Figure 3 Overlaps of transcriptomes and sub-transcriptomes. (A) Main overlaps of hESC and hESC-derived cell transcriptomes. Grey, hESC transcriptome; Blue, endothelial cell transcriptome; Red: fibroblast transcriptome; Green: mixture of hESC-derived cell transcriptome. (B) The overlaps of hESC sub-transcriptomes. The hESC transcriptome is composed of 8,934 mRNAs in total with a hESC-specific part (1,010 mRNAs, brown part), a common part (1,933 mRNAs, blue part) shared with the hESC-derived cells, and the rest of the mRNAs (grey). Sub-transcriptomes can be highlighted: the HS binding proteins part (191 mRNAs, specific in red and common in pink); the extracellular part (EC) without HS binding proteins (576 mRNAs, specific in orange and common in purple); the transcription factor related part (TF, 721 mRNAs, specific in yellow and common in light blue).

constitute the high coverage hESC transcriptome (Table S1). To establish hESC specific expression profiles, three different early hESC-derived cell transcriptomes were extracted from analogous fibroblast (5,086 mRNAs), endothelial cells (5,522 mRNAs) or mixed hESC-derived cells (10,730 mRNAs, Table 1 and Table S1).

The mRNAs specifically expressed by the hESCs (1,010 mRNAs) and those common to hESCs and hESC-derived cells (1,933 mRNAs) were identified by comparing the hESC transcriptome with the hESC-derived transcriptomes (Fig. 3A). Gene Ontology (GO) annotation database (Ashburner et al., 2000) was then used to identify the hESC transcription factor (TF) related (721 mRNAs) and extracellular (EC) transcripts. In this last set of mRNAs, a distinction between transcripts coding for HS binding proteins (191 mRNAs) and non-binding proteins (576 mRNAs, Fig. 3B and Table S1) was enabled by a published list of HS binding proteins (Ori, Wilkinson & Fernig, 2008).

Transcriptome analysis showed that genes known to be involved in stemness were represented in this hESC transcriptome, such as POU class 5 homeobox 1 (POU5F1, which encodes OCT4 protein) (Nichols et al., 1998) and SOX2 (Avilion et al., 2003). As expected, some of these were in the hESC specific subset, such as the telomerase reverse transcriptase (TERT) (Yang et al., 2008) and growth differentiation factor 3 (GDF3) (Levine & Brivanlou, 2006) (Table 2A). Interestingly, NANOG (Chambers et al., 2003) was not present here. Some germ layer markers were also found in the hESC transcriptome, but they were never specific (Table 2B). Lastly, many common additions to cell culture medium, which have been observed to facilitate hESC growth in vitro, such as FGF2 (Eiselleova et al., 2009;
Table 1 Microarray datasets analysis. The access number (second column) gives access to the dataset in ArrayExpress database. Cell types and cell lines (first column), main cell culture conditions (third column), publications linked to the dataset (when available, fourth column) and the number of microarrays used per analysis (fifth column) are specified. Expressed gene lists for each algorithm (RMA, GC-RMA and MAS5.0) as the total and intersection lists are presented. Four hESC datasets (E-GEOD-6561, -15148, -18265 and -26672) have been used to build mix1. Six hESC-derived cell datasets (E-GEOD-9196, -9832, -9940, -14897, -19735 and -21668) have been used to build mix2. Datasets in bold represent the final transcriptomes used for further analysis: mix1 for hESCs, E-GEOD-9832 for the fibroblasts, E-GEOD-19735 for the endothelial cells and mix2 for the mixture of hESC-derived cells.

| Cell type (Cell line) | Access number | Linked publication | Main cell culture feature | Number of microarrays | RMA         | GC-RMA      | MAS5.0      | Total | Intersection |
|-----------------------|---------------|---------------------|---------------------------|-----------------------|-------------|-------------|-------------|-------|--------------|
| hESCs (H14)           | E-GEOD-6561   | (Baker et al., 2007)| On feeder cells (irradiated MEFs) FGF2 (4 ng/mL) 20% KnockOut SR | 4                    | 9,672    | 8,680      | 9,822       | 11,930 | 7,088        |
| hESCs (H1, H7, H9, H13, H14) | E-GEOD-15148 | (Yu et al., 2009)  | On feeder cells (irradiated MEFs) FGF2 (100 ng/mL) 20% KnockOut SR OR On feeder-free matrigel Conditioned medium | 10                  | 8,798    | 10,554     | 10,293      | 12,467 | 7,395        |
| hESCs                 | E-GEOD-18265  | /                   | On feeder cells (inactivated HFFs) FGF2 (10 ng/mL) 20% KnockOut SR | 5                    | 9,602    | 11,325     | 10,966      | 13,499 | 7,791        |
| hESCs (H1)            | E-GEOD-26672  | (Hu et al., 2011)  | On feeder cells (irradiated MEFs) FGF2 (4 ng/mL) 20% KnockOut SR | 5                    | 9,656    | 11,285     | 10,843      | 12,790 | 8,235        |
| hESCs Mix1            | /             | /                   |                           | 24                  | 11,001   | 12,173     | 11,546      | 14,043 | 8,934        |
| Embryoid bodies       | E-GEOD-9196   | (Lu et al., 2007)  |                           | 9                   | 5,142    | 6,308      | 6,667       | 8,935  | 3,576        |
| Embryoid bodies       | E-GEOD-9940   | /                   |                           | 12                  | 6,939    | 8,432      | 7,309       | 11,517 | 3,944        |
| Embryoid bodies       | E-GEOD-14897  | (Si-Tayeb et al., 2010) |                           | 3                   | 1,356    | 2,485      | 5,009       | 5,812  | 942          |
| Embryoid bodies       | E-GEOD-19735  | /                   |                           | 4                   | 7,166    | 9,237      | 8,448       | 11,085 | 5,522        |
| Embryoid bodies       | E-GEOD-21668  | (Evseenko et al., 2010) |                           | 2                   | 704      | 1,832      | 1,156       | 2,079  | 583          |
| Mesenchymal progenitors| E-GEOD-9832   | (Park et al., 2008) | Embryoid bodies E-GEOD-9940 / | 3                   | 6,471    | 7,510      | 8,072       | 9,795  | 5,086        |
| Mesenchymal progenitors| E-GEOD-14897  | (Si-Tayeb et al., 2010) | Embryoid bodies E-GEOD-19735 / | 3                   | 1,669    | 2,659      | 4,017       | 4,864  | 1,299        |
| Neural progenitors     | E-GEOD-9832   | (Park et al., 2008) | Neural progenitors E-GEOD-9940 / | 12                  | 6,939    | 8,432      | 7,309       | 11,517 | 3,944        |
| Embryoid bodies       | E-GEOD-19735  | /                   | Embryoid bodies E-GEOD-14897 / | 3                   | 1,356    | 2,485      | 5,009       | 5,812  | 942          |
| Hepatic cells          | E-GEOD-14897  | (Si-Tayeb et al., 2010) | Embryoid bodies E-GEOD-19735 / | 3                   | 1,669    | 2,659      | 4,017       | 4,864  | 1,299        |
| Endothelial cells      | E-GEOD-9832   | (Park et al., 2008) | Endothelial cells E-GEOD-14897 / | 3                   | 6,471    | 7,510      | 8,072       | 9,795  | 5,086        |
| Differentiated cells   | Mix2          | /                   | Differentiated cells Mix2 / | 48                  | 16,174   | 14,172     | 12,134      | 17,458 | 10,730       |

Notes.
MEFs, mouse embryonic fibroblasts; HFFs, human foreskin fibroblasts; SR, serum replacer.
| Marker/Family | Acronym | Name | Transcriptome | GO term |
|--------------|---------|------|---------------|---------|
| A | Embryonic stem cell | PTEN | phosphatase and tensin homolog | hESC (COMMON) | CS/CA/CC/Cco |
| | | TERT | telomerase reverse transcriptase | hESC (SPECIFIC) | |
| | | GDF3 | growth differentiation factor 3 | hESC (SPECIFIC) | EC non-HS |
| | | NODAL | nodal homolog (mouse) | hESC (SPECIFIC) | CCo/EC non-HS |
| | | ZIC3 | Zic family member 3 | hESC, Mix | TF |
| | | SOX2 | SRY (sex determining region Y)-box 2 | hESC, Mix | CCo/TF |
| | | POU5F1 | POU class 5 homeobox 1 | hESC, Mix | |
| | Ectoderm | NEFH | neurofilament, heavy polypeptide | hESC (COMMON) | CS |
| | | TUBB3 | tubulin, beta 3 class III | hESC, Mix | CCo |
| | Endoderm | KRT19 | keratin 19 | hESC (COMMON) | CS |
| | | SOX7 | SRY (sex determining region Y)-box 7 | hESC (COMMON), hESC, Endo, Mix | CCo/TF |
| | | KDR | kinase insert domain receptor | hESC, Mix | CA/CCo/HS |
| | | PDGFRA | platelet-derived growth factor receptor, alpha polypeptide | hESC (COMMON) | CS/CA/CCo |
| | | VIM | vimentin | hESC (COMMON) | CS |
| | Fibronectin | FN1 | fibronectin 1 | hESC (COMMON) | CA/HS |
| | | ITGA5 | integrin, alpha 5 (fibronectin receptor, alpha polypeptide) | hESC, Mix | CA/CCo/J/HS |
| | | ITGB1 | integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | hESC, Endo, Mix | CS/CA/CCo/J/HS |
| | Fibroblast growth factor | FGF2 | fibroblast growth factor 2 | hESC (COMMON) | CC/CCo/HS/TF |
| | | FGF1 | fibroblast growth factor receptor 1 | hESC (COMMON) | CC/CCo/HS |
| | | FGF2 | fibroblast growth factor receptor 2 | hESC, Endo, Mix | CC/CCo/HS |
| | | FGF3 | fibroblast growth factor receptor 3 | hESC, Endo, Mix | CCo/J/HS |
| | | FGF4 | fibroblast growth factor receptor 4 | hESC (SPECIFIC) | CCo/J/HS |
| | Activin A | ACVR1B | activin A receptor, type IB (ALK4) | hESC (COMMON) | CC/CCo/EC non-HS |
| | | ACVR1C | activin A receptor, type IC | hESC (SPECIFIC) | |
| | | ACVR2A | activin A receptor, type IIA | hESC, F, Mix | CCo |
| | | ACVR2B | activin A receptor, type IIB | hESC, Endo, Mix | CCo/EC non-HS |
| | | INHBA | inhibin, beta A/Activin A | hESC (COMMON) | CC/CCo/HS |

Notes.  
Endo, endothelial cell; F, fibroblast; Mix, mixture of hESC-derived cells; GO term column, GO terms found during the GO extraction; CA, cell adhesion; CC, cell cycle; CCo, cell communication; CS, cytoskeleton organisation; J, cell junction; EC, extracellular part; HS, heparan sulfate binding proteins; TF, transcription factor related part.
Putative extracellular/transcriptional interactomes

As the aim of this study was to learn more about the potential importance of functional links between cell/cell–matrix interactions and transcription, putative protein–protein interaction networks containing only transcriptional and extracellular components (EC+TF) were established by means of the STRING database (Szklarczyk et al., 2011) using transcriptional expression data as a proxy for protein expression profiles. Two interactomes were built: one (called ALL) containing all identified EC+TF proteins, composed of 702 nodes and 3,201 edges (Data S1A), and one (called C+S) containing only those transcripts/proteins that were either specific to hESCs or common to hESCs and hESC-derived cells, comprising 209 nodes and 371 edges (Data S1B).

The average clustering coefficient $C$ (indicating the network cohesiveness) was closer to zero for all randomised networks compared to both ALL and C+S interactomes, implying a significantly higher occurrence of clusters in these selected networks (Fig. 4A).

As observed in previous protein–protein interaction network studies (Albert, Jeong & Barabasi, 2000; Jeong et al., 2001), both selected networks (ALL and C+S) and randomised networks exhibit a scale free structure, where the degree distribution $P(k)$ follows a power-law $P(k) \sim k^{-\gamma}$, involving the presence of hubs (Fig. 4B and Table S2), and the clustering coefficient distribution $C(k)$ is independent of $k$ meaning there is no inherent presence of modules unlike hierarchical networks, even if there was a tendency of the real networks to be hierarchical ($C(k) \sim k^{-\beta}$) compared to the randomised versions (Fig. 4C).

**Vallier, Alexander & Pedersen, 2005** and activin A (**Xiao, Yuan & Sharkis, 2006**) were also present (Table 2C).
These results demonstrate that the EC+TF putative protein–protein interaction networks were suitable for further analysis.

**Enrichment analysis**

GO Biological Processes term and KEGG pathway enrichments were used to determine if the EC+TF putative interactomes contained significantly enriched subsets of proteins. As expected, terms related to EC (extracellular matrix organization), and TF (transcription, DNA templated) appeared. More interestingly, terms relating to development (embryonic development) and pathways already known to be involved in hESC stemness maintenance (transforming growth factor (TGF)-β (James et al., 2005) or wingless-type MMTV integration site family (Wnt) (Sato et al., 2004)) and differentiation (bone morphogenic protein (BMP) signalling (Xu et al., 2005)) were also identified. KEGG Pathways in cancer as well as GO terms of cell differentiation, cell adhesion, cell communication and cell proliferation were represented too (Fig. 5 and Table S3A).

Fewer terms were found to be significantly enriched when only the common and specific parts (from ALL to C+S) were analysed. However, when they were found significant, the vast majority was more enriched, except the terms related to TF (Table S3A). Nuclear-transcribed mRNA catabolic process (representing 56% of ALL and 48% of C+S) and multicellular organismal development (representing 47% of ALL and 54% of C+S) were the most represented non-related terms (Table S3A).

Interestingly, regulation of cellular component movement was well enriched with fold changes in ALL of 5.8 (Homo sapiens as background)/4.6 (hESC as background) and in C+S of 9.4 (Homo sapiens as background)/7.4 (hESC as background). 28%/51% of the proteins belonging to this term in Homo sapiens/hESC were represented in ALL and 17%/31% in C+S (Tables S3A).

These data show that the EC+TF putative interactomes, both ALL and C+S, still contained the subsets of proteins involved in development, cell differentiation, cell adhesion and cell communication.

**Novel proteins potentially associated with stemness**

The final list of potential stemness proteins was established from ALL, the EC+TF putative protein–protein interaction network. This list (called ALL EC+TF) was composed of nodes with hub or bottleneck features, as well as nodes within the specific/common and EC/TF interfaces (Fig. 2). Hubs are thought to be functionally important due to their high number of interactions, while bottlenecks form links between different processes. 58% of the bottlenecks in the ALL network were also hubs. The specific/common interface reflects the links between the more general cell functions and those specific to hESCs. The EC/TF interface represents points of communication between the genome and the cell’s environment, including other cells. The ALL EC+TF contained 387 candidates (49% EC and 55% TF) with 29 specific (8%) and 126 common (33%) nodes. The key transcription factors OCT4 and SOX2 were present as hubs and part of the EC/TF interface (Table S4A).

Considering GO set (TF, EC) enrichment with regards to proteins belonging to common or specific parts of the transcriptome, the specific subset was enriched in non-HS...
Figure 5 GO/KEGG analyses of EC+TF putative interactomes. (A) GO Biological Processes term enrichment (against *Homo sapiens*), in fold change. (B) Percentage of the total number of proteins in *Homo sapiens* related to GO Biological Processes that are present in ALL and C+S putative interactomes. C, common part; S, specific part.

binding EC proteins (1.7-fold change), whereas the common subset was enriched in HS binding proteins (1.6-fold change) (Fig. 6A). In addition the common subset was found to be enriched in both hubs (1.3-fold change) and bottlenecks (1.6-fold change) (Fig. 6B). Finally, hubs were enriched in TF (1.4-fold change) and bottlenecks in HS binding proteins (1.3-fold change, Fig. 6B).

To assess the validity of the candidate prediction, a random ALL_EC+TF list was established the same way using a randomised version of the EC+TF putative interactome
Figure 6 Comparative enrichment trends within the candidate protein list. (A) Enrichments in specific, common and other parts with HS, EC non-HS and TF. (B) Enrichments in HS, EC non-HS and TF parts with EC/TF interface, C/S interface, hubs and bottlenecks. C, common part; S, specific part; EC, extracellular part; HS, heparan sulfate binding proteins; TF, transcription factor related part.

(Tables S4B). The hub subset was identical in both real and random versions of the candidate list due to the way the randomised network was generated. However, the bottleneck subset in the real list had proteins with significantly higher betweenness centrality \((7,456 \pm 835,\) paired sample test, \(n = 134,\) \(p\)-value < 0.001) than the one in the random list (0.0108 ± 0.0005). Moreover, the random list with 581 proteins retained 83% of the original EC+TF putative interactome against 55% for the real list. The comparison between the real list of candidates and its random version showed that the filtering process was meaningful.

Three shortened lists were generated from ALL EC+TF list to decrease the number of candidates by either keeping only EC proteins (ALL EC, 188 proteins, Table S4C) or/and C+S proteins (C+S EC+TF, 155 proteins, Table S4D and C+S EC, 92 proteins, Table S4E) as described in Fig. 2. 59% of the common proteins in the longest ALL EC+TF list and 62% of the specific ones were conserved in the shortest C+S EC list. Similarly, 9% of the hubs and 20% of the bottlenecks were kept.

To determine if each list and each subset (hubs, bottlenecks and interfaces, as well as specific, common and other proteins from the complete (ALL EC+TF) to the shortest (C+S EC) list) still contained proteins potentially involved in stemness maintenance, we undertook further GO Biological Processes term and KEGG pathway enrichments (Table S3B–I). Only the subset containing the hESC-specific proteins was found without any significant enrichment regarding the analysed terms and pathways (Table S3C). However, the most represented term in both specific subsets from the ALL EC+TF and ALL EC, as well as in the four full lists and in all other subsets, was multicellular organismal development (Table S3B–I).
Again, terms and pathways related to TF appeared in ALL_EC+TF and C+S_EC+TF lists, as well as in all the other subsets of these two lists (Table S3B,D–I). These TF terms and pathways were logically lost in the ALL_EC and C+S_EC lists and subsets.

GO terms related to cell differentiation, cell adhesion, cell communication, cell movement or cell proliferation, and KEGG pathways of cancer were still significantly enriched in the four lists and in the vast majority of the analysed subsets (Table S3B,D–I).

These data demonstrate that the four lists of candidates, as well as each subset of proteins (hubs, bottlenecks, specific/common and EC/TF interfaces) incorporated proteins involved in development and cell communication. Focusing on the EC proteins that were either specific to hESCs or common to hESCs and hESC-derived cells allowed us to reduce the number of candidates to 92 proteins (Table 3 and Table S4E), while insuring that proteins potentially involved in stemness maintenance were retained. Among these proteins, some are already known to be required for maintenance of hESC stemness, either directly, such as NODAL (James et al., 2005; Vallier, Alexander & Pedersen, 2005), FGF2 (Eiselleova et al., 2009; Vallier, Alexander & Pedersen, 2005) and activin A (Xiao, Yuan & Sharkis, 2006), or indirectly through signalling pathways such as TGF-β (James et al., 2005) or Wnt (Sato et al., 2004). Other proteins are also known to play a role in mouse ESC pluripotency, but not yet in hESC, such as the transcription factor 3 (TCF3) (Cole et al., 2008). However, for the majority of candidates, including titin, nothing is known yet about their functions in the context of hESCs.

DISCUSSION

We provide a novel picture of the hESC transcriptome built from a meta-analysis and allowing the in silico analysis of a putative hESC protein–protein interaction network. This systems-level approach has been used to identify proteins potentially involved in the maintenance of stemness.

Transcriptomic data provide the most comprehensive insight into variations in cell type or condition specific gene expression profiles. Therefore, data from multiple microarray studies were chosen to generate putative interactomes due to the lack of corresponding proteomic profiles. Even if mRNA and protein levels have been suggested to correlate weakly, this correlation may be stronger than anticipated, though this depends on the techniques used to measure mRNA (Li, Bickel & Biggin, 2014; Pascal et al., 2008; Schwanhäusser et al., 2011; Schwanhäusser et al., 2013). Thus, the present study provides a predictive qualitative insight into sub-networks of proteins, which may mediate or maintain human stem cell pluripotency.

The decision to selectively include genes only found by three different algorithms allowed a reduction in the number of false positives in the whole transcriptome, but probably amplified the number of false negatives, which may explain the absence of NANOG. Regarding the specific/common distinction, this pipeline permitted confidence about the common mRNA subset, whereas it likely increased the false positive rate in the specific mRNA subset, which is still half of the common one. However, the use
Table 3 The list of candidates, an overview. The ‘hubs’ column gives the degree; the ‘bottlenecks’ column gives the betweenness; the ‘S/C’ column indicates if the protein is in the specific/common interface; the ‘EC/TF’ column indicates if the protein is in the EC/TF interface; the ‘KEGG pathway’ column indicates the number of pathway involving each protein (see Table S4 for a complete list).

| Acronym | Name                              | GO term      | Hubs | Bottlenecks | S/C | EC/TF | KEGG pathway |
|---------|-----------------------------------|--------------|------|-------------|-----|-------|--------------|
| ACTN4   | actinin, alpha 4                  | EC non-HS/CS | 17   | X           | X   | 4     |              |
| ACVR1B  | activin A receptor, type IB (ALK4)| EC non-HS/CC/CCo | X     | X           |     | 1     |              |
| ADM     | adrenomedullin                    | EC non-HS/CCo | 4050.8 | X           | X   | 0     |              |
| BMP2    | bone morphogenetic protein 2      | HS/CC/CCo    | 2693.9 | X           | X   | 3     |              |
| DMD     | dystrophin                        | EC non-HS/CS/CCo | X     |             |     | 0     |              |
| FGFR1   | fibroblast growth factor receptor 1| HS/CC/CCo   | 2634.2 | X           | X   | 5     |              |
| FN1     | fibronectin 1                     | HS/CA        | 26   | 6988.8      | X   | 5     |              |
| IL6     | Interleukin 6                     | HS/CCo       | 6    | X           |     | 4     |              |
| INHBA   | inhibin, beta A/Activin A         | HS/CC/CCo    | X    |             |     | 2     |              |
| ITGA6   | integrin, alpha 6 (CD49f)         | EC non-HS/CA/CCo/J | 40 | 15218.1 | X   | 6     |              |
| ITGAV   | integrin, alpha V (vitronectin receptor) | HS/CA/CCo | 40 | 12409.4 | X   | 6     |              |
| JAM3    | junctional adhesion molecule 3    | EC non-HS/CA/CCo/J | X     | X           |     | 2     |              |
| LAMA1   | laminin, alpha 1                  | HS/CA/CCo    | 15   | X           |     | 4     |              |
| MET     | hepatocyte growth factor receptor | HS/CS/CC/CCo | 24   | 10501.7     | X   | X     | 6            |
| PLAT    | plasminogen activator, tissue     | HS/CCo       | 2552.8 | X           |     | 0     |              |
| PLAU    | plasminogen activator, urokinase  | HS/CA/CCo    | X    |             |     | 1     |              |
| SERPINE1| serpin peptidase inhibitor, clade E, member 1 | HS/CA/CCo | 24 | 10022.8 | X   | 1     |              |
| SERPIN1| serpin peptidase inhibitor, clade I, member 1 | EC non-HS/CA | X     |             |     | 0     |              |
| TGFBI   | transforming growth factor, beta 2| HS/CA/CC/CCo | 25 | 10580.8 | X   | X     | 6            |
| THBS1   | thrombospondin 1                  | HS/CA/CC/CCo | 2066.0 | X           |     | 5     |              |
| VEGFA   | vascular endothelial growth factor A | HS/CA/CCo | 16 | 6817.1 | X   | X     | 6            |
| CDH8    | cadherin 8, type 2                | HS/CA        | X    |             | X   | 0     |              |
| FGFI    | fibroblast growth factor 4        | HS/CA/CCo    | X    |             | X   | 3     |              |
| FGFR4   | fibroblast growth factor receptor 4| HS/CCo    | X    |             | X   | 4     |              |
| IDE     | insulin-degrading enzyme          | EC non-HS/CCo | X    |             |     | 0     |              |
| INHBE   | inhibin, beta E                   | EC non-HS    | X    |             |     | 2     |              |
| NODAL   | nodal homolog (mouse)             | EC non-HS/CCo | X    |             | X   | 1     |              |
| PLXNB1  | plexin B1                         | EC non-HS/CCo | X    |             |     | 0     |              |
| TTN     | titin                             | EC non-HS/CS/CC | X    |             | X   | 0     |              |
| WIF1    | WNT inhibitory factor 1           | EC non-HS/CCo | X    |             | X   | 1     |              |

Notes.
GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; C, common part; S, specific part; EC, extracellular part; TF, transcription factor related part; J, cell junction.

of transcriptomic data from different hESC lines cultured under different conditions highlighted the core transcriptome of these cells.

Not all mRNAs were represented in the putative protein–protein interaction network, probably because coverage of human protein–protein interactions in all databases, including STRING, remains incomplete (De Las Rivas & Fontanillo, 2010). High edge stringency limits imposed in this study should minimise inclusion of false positive interactions (De Las Rivas & Fontanillo, 2010), thereby increasing confidence in the relevance and utility of predicted networks.
The scale-free nature of the EC+TF putative interactomes mean that they should exhibit a high error tolerance thanks to redundancy and a high attack vulnerability, due to the presence of hubs (Albert, Jeong & Barabasi, 2000).

Even incomplete interactomes are very complex structures. In order to focus on the likely most important proteins within this interactome, four selection criteria were applied, the first being the selection of hESC hubs. These proteins constitute a small, but often essential part of the interactome (Awan et al., 2007). For example, deletion of just one hub in yeast is often lethal (Jeong et al., 2001). The second was the selection of bottlenecks, which link processes and so permit cross-talk. The third and the fourth criteria involved were that proteins had to be in the specific/common or EC/TF interfaces. These interfaces are posited to be important, as they reflect communication links between the nucleus and the extracellular matrix, and between the specific and common proteins, which ultimately make hESCs different from other cell types.

Interestingly, the GO term related to cell motility regulation was strongly represented in the candidate lists. Cell movement is a key component of morphogenesis. It is usually accomplished by three steps (protrusion, adhesion and de-adhesion) where cytoskeleton and ECM are involved (Ananthakrishnan & Ehrlicher, 2007). This may be significant as recent data indicate that cell motion may be an intrinsic feature of hESCs (Li et al., 2010).

Regulation of cell proliferation also appeared in our analysis of candidate lists. This may be significant, as cell proliferation is a key property of hESCs, since these cells are able to proliferate almost indefinitely in vitro (Miura, Mattson & Rao, 2004). This capability is sustained by the EC part with growth factors (Activin A (Baxter et al., 2009) and FGF2 (Xu et al., 2005)) and ECM molecules (fibronectin (Baxter et al., 2009) or laminin (Rodin et al., 2010)), as well as by the TF part through the Smad signalling pathway (James et al., 2005; Vallier, Alexander & Pedersen, 2005). Cell proliferation can also be linked to the significant enrichment of cancer pathways in hESCs. Several links arise between cancer and hESCs, for example, the formation of teratomas as a test to assess pluripotency.

**CONCLUSION**
Mechanisms involved in stemness are complex, multi-level and determined by the intrinsic cell potential, cell/cell and cell/matrix interactions. The meta-analysis of transcriptomic data in this study has allowed the construction of a hESC putative protein–protein interaction network from which novel ECM proteins have been identified as potential stemness regulators.

Networks are a snapshot of a dynamic model (Assmus et al., 2006; Peltier & Schaffer, 2010). Notions of attractors (or cell stable stationary states), landscapes formed with valleys (attractors) and hills (barriers between attractors), and cell state transitions described by dynamic systems theory will complete this systems biology approach and bring new hypotheses on hESC behaviour (MacArthur, Ma’ayan & Lemischka, 2008; MacArthur, Ma’ayan & Lemischka, 2009; Peltier & Schaffer, 2010; Roeder & Radtke, 2009).
ACKNOWLEDGEMENTS
Analyses were performed using BRB-ArrayTools developed by Dr Richard Simon and BRB-ArrayTools Development Team.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding
This work was partly funded by North West Cancer Research, Cancer and Polio Research Fund, Biomedical Research Unit award from the National Institute for Health Research, Royal College of Surgeons of England-Ethicon Research Fellowship and BBSRC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
North West Cancer Research.
Cancer and Polio Research Fund.
National Institute for Health Research.
Royal College of Surgeons of England-Ethicon Research Fellowship.
BBSRC.

Competing Interests
The authors declare there are no competing interests.

Author Contributions
• Virginie Mournetas conceived and designed the experiments, performed the experiments, analyzed the data, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.
• Quentin M. Nunes conceived and designed the experiments, contributed reagents/materials/analysis tools, wrote the paper, reviewed drafts of the paper.
• Patricia A. Murray, Christopher M. Sanderson and David G. Fernig conceived and designed the experiments, wrote the paper, reviewed drafts of the paper.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.618#supplemental-information.

REFERENCES
Albert R, Jeong H, Barabasi AL. 2000. Error and attack tolerance of complex networks. Nature 406:378–382 DOI 10.1038/35019019.
Ananthakrishnan R, Ehrlicher A. 2007. The forces behind cell movement. International Journal of Biological Sciences 3:303–317 DOI 10.7150/ijbs.3.303.
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G, The Gene Ontology Consortium. 2000. Gene ontology: tool for the unification of biology. *Nature Genetics* 25:25–29 DOI 10.1038/75556.

Assmus HE, Herwig R, Cho KH, Wolkenhauer O. 2006. Dynamics of biological systems: role of systems biology in medical research. *Expert Review of Molecular Diagnostics* 6:891–902 DOI 10.1586/14737159.6.6.891.

Atlasi Y, Mowla SJ, Ziaee SA, Gokhale PJ, Andrews PW. 2008. OCT4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells. *Stem Cells* 26:3068–3074 DOI 10.1634/stemcells.2008-0530.

Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. 2003. Multipotent cell lineages in early mouse development depend on SOX2 function. *Genes and Development* 17:126–140 DOI 10.1101/gad.224503.

Awan A, Bari H, Yan F, Moksong S, Yang S, Chowdhury S, Cui Q, Yu Z, Purisima EO, Wang E. 2007. Regulatory network motifs and hotspots of cancer genes in a mammalian cellular signalling network. *IET Systems Biology* 1(5):292–297 DOI 10.1049/iet-syb:20060068.

Aznar J, Gomez I. 2012. Possible clinical usefulness of embryonic stem cells. *Revista Clinica Espanola* 212:403–406 DOI 10.1016/j.rce.2012.05.006.

Babaie Y, Herwig R, Greber B, Brink TC, Wruk W, Groth D, Lehrach H, Burdon T, Adjaye J. 2007. Analysis of Oct4-dependent transcriptional networks regulating self-renewal and pluripotency in human embryonic stem cells. *Stem Cells* 25:500–510 DOI 10.1634/stemcells.2006-0426.

Baker DE, Harrison NJ, Maltby E, Smith K, Moore HD, Shaw PJ, Heath PR, Holden H, Andrews PW. 2007. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. *Nature Biotechnology* 25:207–215 DOI 10.1038/nbt1285.

Baxter MA, Camarasa MV, Bates N, Small F, Murray P, Edgar D, Kimber SJ. 2009. Analysis of the distinct functions of growth factors and tissue culture substrates necessary for the long-term self-renewal of human embryonic stem cell lines. *Stem Cell Research* 3(1):28–38 DOI 10.1016/j.scr.2009.03.002.

Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Gunther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK, Melton DA, Jaenisch R, Young RA. 2005. Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell* 122:947–956 DOI 10.1016/j.cell.2005.08.020.

Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A. 2003. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. *Cell* 113:643–655 DOI 10.1016/S0092-8674(03)00392-1.

Chavez L, Bais AS, Vingron M, Lehrach H, Adjaye J, Herwig R. 2009. In silico identification of a core regulatory network of OCT4 in human embryonic stem cells using an integrated approach. *BMC Genomics* 10:314 DOI 10.1186/1471-2164-10-314.

Cole MF, Johnstone SE, Newman JJ, Kagey MH, Young RA. 2008. Tcf3 is an integral component of the core regulatory circuitry of embryonic stem cells. *Genes and Development* 22:746–755 DOI 10.1101/gad.1642408.

De Las Rivas J, Fontanillo C. 2010. Protein–protein interactions essentials: key concepts to building and analyzing interactome networks. *PLoS Computational Biology* 6:e1000807 DOI 10.1371/journal.pcbi.1000807.
Eiselleova L, Matulka K, Kriz V, Kunova M, Schmidtova Z, Neradil J, Tichy B, Dvorakova D, Pospisilova S, Hampl A, Dvorak P. 2009. A complex role for FGF-2 in self-renewal, survival, and adhesion of human embryonic stem cells. *Stem Cells* 27:1847–1857 DOI 10.1002/stem.128.

Evseenko D, Schenke-Layland K, Dravid G, Zhu Y, Hao QL, Scholes J, Wang XC, Maclellan WR, Crooks GM. 2009. Identification of the critical extracellular matrix proteins that promote human embryonic stem cell assembly. *Stem Cells and Development* 18:919–928 DOI 10.1089/scd.2008.0293.

Evseenko D, Zhu Y, Schenke-Layland K, Kuo J, Latour B, Ge S, Scholes J, Dravid G, Li X, Maclellan WR, Crooks GM. 2010. Mapping the first stages of mesoderm commitment during differentiation of human embryonic stem cells. *Proceedings of the National Academy of Sciences of the United States of America* 107:13742–13747 DOI 10.1073/pnas.1002077107.

Fong H, Hohenstein KA, Donovan PJ. 2008. Regulation of self-renewal and pluripotency by Sox2 in human embryonic stem cells. *Stem Cells* 26:1931–1938 DOI 10.1634/stemcells.2007-1002.

Greber B, Wu G, Bernemann C, Joo JY, Han DW, Ko K, Tapia N, Sabour D, Sterneckert J, Tesar P, Scholer HR. 2010. Conserved and divergent roles of FGF signaling in mouse epiblast stem cells and human embryonic stem cells. *Cell Stem Cell* 6:215–226 DOI 10.1016/j.stem.2010.01.003.

Hay DC, Sutherland L, Clark J, Burdon T. 2004. Oct-4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells. *Stem Cells* 22:225–235 DOI 10.1634/stemcells.22-2-225.

Huang DW, Sherman BT, Lempicki RA. 2009a. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Research* 37:1–13 DOI 10.1093/nar/gkn923.

Huang DW, Sherman BT, Lempicki RA. 2009b. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nature Protocols* 4:44–57 DOI 10.1038/nprot.2008.211.

Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. 2003. Summaries of Affymetrix GeneChip probe level data. *Nucleic Acids Research* 31:e15 DOI 10.1093/nar/gng015.

James D, Levine AJ, Besser D, Hemmati-Brivanlou A. 2005. TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. *Development* 132:1273–1282 DOI 10.1242/dev.01706.

Jensen J, Hyllner J, Bjorquist P. 2009. Human embryonic stem cell technologies and drug discovery. *Journal of Cellular Physiology* 219:513–519 DOI 10.1002/jcp.21732.

Jeong H, Mason SP, Barabasi AL, Oltvai ZN. 2001. Lethality and centrality in protein networks. *Nature* 411:41–42 DOI 10.1038/35075138.

Kanehisa M, Goto S. 2000. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Research* 28:27–30 DOI 10.1093/nar/28.1.27.
Keller G. 2005. Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes and Development 19:1129–1155 DOI 10.1101/gad.1303605.

Koh GC, Porras P, Aranda B, Hermjakob H, Orchard SE. 2012. Analyzing protein–protein interaction networks. Journal of Proteome Research 11:2014–2031 DOI 10.1021/pr201211w.

Leis O, Eguiaara A, Lopez-Arrilibaraga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R, Martin AG. 2012. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 31:1354–1365 DOI 10.1038/onc.2011.338.

Levine AJ, Brivanlou AH. 2006. GDF3, a BMP inhibitor, regulates cell fate in stem cells and early embryos. Development 133:209–216 DOI 10.1242/dev.02192.

Li JJ, Bickel PJ, Biggin MD. 2014. System wide analyses have underestimated protein abundances and the importance of transcription in mammals. PeerJ 2:e270 DOI 10.7717/peerj.270.

Li L, Wang BH, Wang S, Moalim-Nour L, Mohib K, Lohnes D, Wang L. 2010. Individual cell movement, asymmetric colony expansion, rho-associated kinase, and E-cadherin impact the clonogenicity of human embryonic stem cells. Biophysical Journal 98:2442–2451 DOI 10.1016/j.bpj.2010.02.029.

Li W, Wei W, Zhu S, Zhu J, Shi Y, Lin T, Hao E, Hayek A, Deng H, Ding S. 2009. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 4:16–19 DOI 10.1016/j.stem.2008.11.014.

Liedtke S, Ennczmann J, Waclawczyk S, Wernet P, Kogler G. 2007. Oct4 and its pseudogenes confuse stem cell research. Cell Stem Cell 1:364–366 DOI 10.1016/j.stem.2007.09.003.

Lu SJ, Hipp JA, Feng Q, Hipp JD, Lanza R, Atala A. 2007. GeneChip analysis of human embryonic stem cell differentiation into hemangioblasts: an in silico dissection of mixed phenotypes. Genome Biology 8:R240 DOI 10.1186/gb-2007-8-11-r240.

Ludwig TE, Levenstein ME, Jones JM, Berggren WT, Mitichen ER, Frane JL, Crandall LJ, Daigh CA, Conard KR, Piekarczyk MS, Llanas RA, Thomson JA. 2006. Derivation of human embryonic stem cells in defined conditions. Nature Biotechnology 24:185–187 DOI 10.1038/nbt1177.

MacArthur BD, Ma’ayan A, Lemischka IR. 2008. Toward stem cell systems biology: from molecules to networks and landscapes. Cold Spring Harbor Symposia on Quantitative Biology 73:211–215 DOI 10.1101/sqb.2008.73.061.

MacArthur BD, Ma’ayan A, Lemischka IR. 2009. Systems biology of stem cell fate and cellular reprogramming. Nature Reviews Molecular Cell Biology 10:672–681.

Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S, Guenther MG, Johnston WK, Wernig M, Newman J, Calabrese JM, Dennis LM, Volkert TL, Gupta S, Love J, Hannett N, Sharp PA, Bartel DP, Jaenisch R, Young RA. 2008. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 134:521–533 DOI 10.1016/j.cell.2008.07.020.

Melkoumian Z, Weber JL, Weber DM, Fadeev AG, Zhou Y, Dolley-Sonneville P, Yang J, Qiu L, Priest CA, Shogbon C, Martin AW, Nelson J, West P, Betlzer JP, Pal S, Brandenberger R. 2010. Synthetic peptide-acrylate surfaces for long-term self-renewal and cardiomyocyte differentiation of human embryonic stem cells. Nature Biotechnology 28:606–610 DOI 10.1038/nbt.1629.

Miura T, Mattson MP, Rao MS. 2004. Cellular lifespan and senescence signaling in embryonic stem cells. Aging Cell 3:333–343 DOI 10.1111/j.1474-9728.2004.00134.x.

Muller FJ, Laurent LC, Kostka D, Ulitsky I, Williams R, Lu C, Park IH, Rao MS, Shamir R, Schwartz PH, Schmidt NO, Loring JF. 2008. Regulatory networks define phenotypic classes of human stem cell lines. Nature 455:401–405 DOI 10.1038/nature07213.
Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Scholer H, Smith A. 1998. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. *Cell* 95:379–391 DOI 10.1016/S0092-8674(00)81769-9.

Ori A, Wilkinson MC, Fernig DG. 2008. The heparanome and regulation of cell function: structures, functions and challenges. *Frontiers in Bioscience* 13:4309–4338 DOI 10.2741/3007.

Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ. 2008. Reprogramming of human somatic cells to pluripotency with defined factors. *Nature* 451:141–146 DOI 10.1038/nature06534.

Parkinson H, Kapushesky M, Shojatalab M, Abeygunawardena N, Coulson R, Farne A, Holloway E, Kolesnykov N, Lilja P, Lukk M, Mani R, Rayner T, Sharma A, William E, Sarkans U, Brazma A. 2007. ArrayExpress—a public database of microarray experiments and gene expression profiles. *Nucleic Acids Research* 35:D747–D750 DOI 10.1093/nar/gkl995.

Pascal LE, True LD, Campbell DS, Deutsch EW, Risk M, Coleman IM, Eichner LJ, Nelson PS, Liu AY. 2008. Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. *BMC Genomics* 9:246 DOI 10.1186/1471-2164-9-246.

Peltier J, Schaffer DV. 2010. Systems biology approaches to understanding stem cell fate choice. *IET Systems Biology* 4:1–11 DOI 10.1049/iet-syb.2009.0011.

Pera MF, Reubinoff B, Trounson A. 2000. Human embryonic stem cells. *Journal of Cell Science* 113(Pt 1):5–10.

Pierantozzi E, Gava B, Manini I, Roviello F, Marotta G, Chiarelli M, Sorrentino V. 2011. Pluripotency regulators in human mesenchymal stem cells: expression of NANOG but not of OCT-4 and SOX-2. *Stem Cells and Development* 20:915–923 DOI 10.1089/scd.2010.0353.

Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, Robson P. 2005. Transcriptional regulation of nanog by OCT4 and SOX2. *Journal of Biological Chemistry* 280:24731–24737 DOI 10.1074/jbc.M502573200.

Rodin S, Domogatskaya A, Strom S, Hansson EM, Chien KR, Inzunza J, Hovatta O, Tryggvason K. 2010. Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511. *Nature Biotechnology* 28:611–615 DOI 10.1038/nbt.1620.

Roeder I, Radtke F. 2009. Stem cell biology meets systems biology. *Development* 136:3525–3530 DOI 10.1242/dev.040758.

Sato N, Meijer L, Skalsounis I, Greengard P, Brivanlou AH. 2004. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. *Nature Medicine* 10:55–63 DOI 10.1038/nm979.

Schwanhäusser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. 2011. Global quantification of mammalian gene expression control. *Nature* 473:337–342 DOI 10.1038/nature10098.

Schwanhäusser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. 2013. Corrigendum: global quantification of mammalian gene expression control. *Nature* 495:126–127 DOI 10.1038/nature11848.

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. 2003. Cytoscape: a software environment for integrated models of biomolecular interaction networks. * Genome Research* 13:2498–2504 DOI 10.1101/gr.1239303.

Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. 2007. Analysis of gene expression data using BRB-ArrayTools. *Cancer Informatics* 3:11–17.

Si-Tayeb K, Noto FK, Nagaoaka M, Li J, Battle MA, Duris C, North PE, Dalton S, Duncan SA. 2010. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. *Hepatology* 51:297–305 DOI 10.1002/hep.23354.
Stelling MP, Lages YM, Tovar AM, Mourao PA, Rehen SK. 2013. Matrix-bound heparan sulfate is essential for the growth and pluripotency of human embryonic stem cells. *Glycobiology* 23:337–345 DOI 10.1093/glycob/cws133.

Sun Y, Villa-Diaz LG, Lam RH, Chen W, Krebsbach PH, Fu J. 2012. Mechanics regulates fate decisions of human embryonic stem cells. *PLoS ONE* 7:e37178 DOI 10.1371/journal.pone.0037178.

Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, Jensen LJ, Von Mering C. 2011. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. *Nucleic Acids Research* 39:D561–D568 DOI 10.1093/nar/gkq973.

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131:861–872 DOI 10.1016/j.cell.2007.11.019.

Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. 1998. Embryonic stem cell lines derived from human blastocysts. *Science* 282:1145–1147 DOI 10.1126/science.282.5391.1145.

Vallier L, Alexander M, Pedersen RA. 2005. Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. *Journal of Cell Science* 118:4495–4509 DOI 10.1242/jcs.02553.

Wobus AM, Boehler KR. 2005. Embryonic stem cells: prospects for developmental biology and cell therapy. *Physiological Reviews* 85:635–678 DOI 10.1152/physrev.00054.2003.

Wu Z, Irizarry R, Gentleman R, Murillo F, Spencer F. 2004. A model based background adjustment for oligonucleotide expression arrays. In press.

Xiao L, Yuan X, Sharkis SJ. 2006. Activin A maintains self-renewal and regulates fibroblast growth factor, Wnt, and bone morphogenetic protein pathways in human embryonic stem cells. *Stem Cells* 24:1476–1486 DOI 10.1634/stemcells.2005-0299.

Xu RH, Peck RM, Li DS, Feng X, Ludwig T, Thomson JA. 2005. Basic FGF and suppression of BMP signaling sustain undifferentiated proliferation of human ES cells. *Nature Methods* 2:185–190 DOI 10.1038/nmeth744.

Yang C, Przyborski S, Cooke MJ, Zhang X, Stewart R, Anyfantis G, Atkinson SP, Saretzki G, Armstrong I, Lako M. 2008. A key role for telomerase reverse transcriptase unit in modulating human embryonic stem cell proliferation, cell cycle dynamics, and in vitro differentiation. *Stem Cells* 26:850–863 DOI 10.1634/stemcells.2007-0677.

Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, Thomson JA. 2009. Human induced pluripotent stem cells free of vector and transgene sequences. *Science* 324:797–801 DOI 10.1126/science.1172482.

Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M. 2007. The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. *PLoS Computational Biology* 3:e59 DOI 10.1371/journal.pcbi.0030059.

Zaehres H, Lensch MW, Daheron L, Stewart SA, Itskovitz-Eldor J, Daley GQ. 2005. High-efficiency RNA interference in human embryonic stem cells. *Stem Cells* 23:299–305 DOI 10.1634/stemcells.2004-0252.

Zangrossi S, Marabese M, Broggin M, Giordano R, D’Erasmo M, Montelatici E, Intini D, Neri A, Pesce M, Rebulla P, Lazzari L. 2007. Oct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker. *Stem Cells* 25:1675–1680 DOI 10.1634/stemcells.2006-0611.